Provectus Biopharmaceuticals (PVCT) Short Interest Ratio & Short Volume $0.07 0.00 (-0.27%) As of 02:18 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock Provectus Biopharmaceuticals Short Interest DataProvectus Biopharmaceuticals (PVCT) has a short interest of 500 shares, representing 0.00% of the float (the number of shares available for trading by the public). This marks a -97.08% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 150,795 shares to cover all short positions.Current Short Interest500 sharesPrevious Short Interest17,100 sharesChange Vs. Previous Month-97.08%Dollar Volume Sold Short$37.45Short Interest Ratio0.0 Days to CoverLast Record DateJune 30, 2025Outstanding Shares420,280,000 sharesShort Percent of Float0.00%Today's Trading Volume389,264 sharesAverage Trading Volume150,795 sharesToday's Volume Vs. Average258% Short Selling Provectus Biopharmaceuticals? Sign up to receive the latest short interest report for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPVCT Short Interest Over TimePVCT Days to Cover Over TimePVCT Percentage of Float Shorted Over Time Provectus Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/2025500 shares $37.45 -97.1%0.0%0 $0.07 6/15/202517,100 shares $1.26 thousand +3,320.0%0.0%0 $0.07 5/31/2025500 shares $42.55 -94.4%0.0%0 $0.09 5/15/20259,000 shares $747.00 +1,700.0%0.0%0.1 $0.08 4/30/2025500 shares $46.45 No ChangeN/A0 $0.09 4/15/2025500 shares $49.25 -92.2%0.0%0 $0.10 3/31/20256,400 shares $640.00 +1,180.0%0.0%0 $0.10 3/15/2025500 shares $50.65 -97.1%0.0%0 $0.10 2/28/202517,500 shares $1.86 thousand +3,400.0%0.0%0.1 $0.11 2/15/2025500 shares $52.20 No Change0.0%0 $0.10 Get the Latest News and Ratings for PVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/2025500 shares $52.80 -97.2%N/A0 $0.11 1/15/202518,000 shares $2.09 thousand +520.7%N/A0 $0.12 12/31/20242,900 shares $348.29 -65.9%N/A0 $0.12 12/15/20248,500 shares $1.09 thousand +214.8%N/A0 $0.13 11/30/20242,700 shares $318.60 +440.0%N/A0 $0.12 11/15/2024500 shares $55.05 -99.2%N/A0 $0.11 10/31/202465,600 shares $7.05 thousand +1,626.3%N/A0.2 $0.11 10/15/20243,800 shares $410.02 -93.5%N/A0 $0.11 9/30/202458,700 shares $5.75 thousand +3,568.8%N/A0.1 $0.10 9/15/20241,600 shares $159.76 -48.4%N/A0 $0.10 8/31/20243,100 shares $279.00 -91.8%N/A0 $0.09 8/15/202437,800 shares $3.28 thousand +404.0%N/A0.1 $0.09 7/31/20247,500 shares $768.75 +87.5%N/A0 $0.10 7/15/20244,000 shares $458.80 +700.0%N/A0 $0.11 6/30/2024500 shares $63.05 No ChangeN/A0 $0.13 6/15/2024500 shares $79.50 -87.8%N/A0 $0.16 5/31/20244,100 shares $690.03 +720.0%N/A0 $0.17 5/15/2024500 shares $97.15 -99.7%N/A0 $0.19 4/30/2024142,600 shares $28.38 thousand +127.8%N/A0.4 $0.20 4/15/202462,600 shares $10.49 thousand -67.2%N/A0.1 $0.17 3/31/2024190,800 shares $34.89 thousand +1,700.0%N/A0.3 $0.18 3/15/202410,600 shares $2.30 thousand -85.7%N/A0 $0.22 2/29/202474,000 shares $11.00 thousand -4.0%N/A0.2 $0.15 2/15/202477,100 shares $10.47 thousand +1,780.5%N/A0.2 $0.14 1/15/202416,300 shares $1.68 thousand -50.6%N/A0.1 $0.10 12/31/202333,000 shares $3.17 thousand +89.7%N/A0.1 $0.10 12/15/202317,400 shares $1.90 thousand +3.0%N/A0 $0.11 11/30/202316,900 shares $2.54 thousand -46.5%N/A0 $0.15 11/15/202331,600 shares $4.74 thousand +179.7%N/A0 $0.15 10/31/202311,300 shares $904.00 +2,160.0%N/A0 $0.08Critical AI announcement set to ignite AI 2.0 (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 10/15/2023500 shares $35.00 No ChangeN/A0 $0.07 9/30/2023500 shares $42.25 -94.8%N/A0 $0.08 9/15/20239,600 shares $943.68 +100.0%N/A0.1 $0.10 8/31/20234,800 shares $489.60 -46.1%N/A0 $0.10 8/15/20238,900 shares $845.50 +1,680.0%N/A0 $0.10 7/31/2023500 shares $54.45 -97.8%N/A0 $0.11 7/15/202322,300 shares $2.80 thousand -64.6%N/A0.1 $0.13 6/30/202363,000 shares $7.13 thousand +63.6%N/A0.1 $0.11 6/15/202338,500 shares $4.58 thousand +7,600.0%N/A0.1 $0.12 5/31/2023500 shares $67.95 -99.4%N/A0 $0.14 5/15/202381,400 shares $11.39 thousand +13,466.7%N/A0.4 $0.14 4/30/2023600 shares $80.22 -81.3%N/A0 $0.13 4/15/20233,200 shares $489.60 -96.4%N/A0 $0.15 3/31/202389,000 shares $14.69 thousand +88,900.0%N/A0.3 $0.17 3/15/2023100 shares $15.40 -99.9%N/A0 $0.15 2/28/2023116,600 shares $18.77 thousand +3,051.4%N/A0.3 $0.16 2/15/20233,700 shares $395.53 -89.5%N/A0 $0.11 1/31/202335,200 shares $4.51 thousand +262.9%N/A0.1 $0.13 1/15/20239,700 shares $1.29 thousand +9,600.0%N/A0 $0.13 12/30/2022100 shares $10.83 -99.0%N/A0 $0.11 12/15/202210,000 shares $1.10 thousand -66.6%N/A0 $0.11 11/30/202229,900 shares $2.78 thousand -45.5%N/A0 $0.09 11/15/202254,900 shares $2.84 thousand +54,800.0%N/A0.1 $0.05 10/31/2022100 shares $5.00 No ChangeN/A0 $0.05 10/15/2022100 shares $4.85 No ChangeN/A0 $0.05 9/30/2022100 shares $4.90 -99.6%N/A0 $0.05 9/15/202225,500 shares $1.35 thousand +8.5%N/A0.1 $0.05 8/31/202223,500 shares $1.28 thousand +2,511.1%N/A0.1 $0.05 8/15/2022900 shares $49.50 +80.0%N/A0 $0.06 7/31/2022500 shares $29.00 +400.0%N/A0 $0.06 7/15/2022100 shares $5.99 -99.6%N/A0 $0.06 6/30/202226,200 shares $1.42 thousand +26,100.0%N/A0.1 $0.05 6/15/2022100 shares $5.30 -96.8%N/A0 $0.05 5/31/20223,100 shares $186.00 -54.4%N/A0 $0.06 5/15/20226,800 shares $357.68 +3,300.0%N/A0 $0.05 4/30/2022200 shares $12.28 +100.0%N/A0 $0.06 4/15/2022100 shares $5.86 No ChangeN/A0 $0.06 3/31/2022100 shares $6.74 No ChangeN/A0 $0.07 3/15/2022100 shares $6.92 -96.7%N/A0 $0.07 2/28/20223,000 shares $206.70 +2,900.0%N/A0 $0.07 2/15/2022100 shares $7.00 -98.7%N/A0 $0.07 1/31/20227,700 shares $500.50 -85.4%N/A0 $0.07 1/15/202252,600 shares $3.68 thousand +39.2%N/A0.1 $0.07 12/31/202137,800 shares $2.08 thousand +37,700.0%N/A0 $0.06 12/15/2021100 shares $5.03 -93.8%N/A0 $0.05 11/30/20211,600 shares $85.76 -61.0%N/A0 $0.05 11/15/20214,100 shares $213.61 +4,000.0%N/A0 $0.05 10/29/2021100 shares $5.62 -99.9%N/A0 $0.06 10/15/202190,700 shares $5.59 thousand -24.6%N/A0.4 $0.06 9/30/2021120,300 shares $7.82 thousand +55.8%N/A0.3 $0.07Critical AI announcement set to ignite AI 2.0 (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 9/15/202177,200 shares $4.86 thousand -45.4%N/A0.2 $0.06 8/31/2021141,300 shares $8.62 thousand -29.4%N/A0.1 $0.06 8/13/2021200,200 shares $13.91 thousand -22.3%N/A0.5 $0.07 7/30/2021257,500 shares $17.90 thousand +29.7%N/A1 $0.07 7/15/2021198,600 shares $13.90 thousand +13.6%N/A0.4 $0.07 6/30/2021174,900 shares $11.98 thousand -3.6%N/A0.7 $0.07 6/15/2021181,500 shares $12.67 thousand -10.4%N/A0.3 $0.07 5/28/2021202,600 shares $14.91 thousand +9.0%N/A0.5 $0.07 5/14/2021185,800 shares $12.43 thousand +16.1%N/A0.6 $0.07 4/30/2021160,000 shares $10.40 thousand No ChangeN/A0.3 $0.07 4/15/2021160,000 shares $10.75 thousand -14.5%N/A0.5 $0.07 3/31/2021187,200 shares $13.12 thousand +10.1%N/A0.3 $0.07 3/15/2021170,000 shares $11.65 thousand +6.3%N/A0.5 $0.07 2/26/2021160,000 shares $11.68 thousand -34.0%N/A0.3 $0.07 2/12/2021242,400 shares $17.70 thousand +25.9%N/A0.3 $0.07 1/29/2021192,600 shares $14.45 thousand -54.3%N/A0.1 $0.08 1/15/2021299,400 shares $20.90 thousand +76.1%N/A0.4 $0.07 12/31/2020160,500 shares $9.29 thousand -46.4%N/A0.3 $0.06 12/15/2020299,400 shares $17.51 thousand +76.1%N/A0.4 $0.06 11/30/2020170,000 shares $10.88 thousand -1.4%N/A0.3 $0.06 11/15/2020172,400 shares $11.59 thousand -46.8%N/A0.6 $0.07 10/30/2020324,100 shares $22.04 thousand +23.8%N/A0.9 $0.07 10/15/2020261,700 shares $19.89 thousand -44.8%N/A0.5 $0.08 9/30/2020473,700 shares $41.02 thousand +194.6%N/A0.7 $0.09 9/15/2020160,800 shares $11.67 thousand +0.2%N/A0.4 $0.07 8/31/2020160,500 shares $12.97 thousand -42.0%N/A0.3 $0.08 8/14/2020276,700 shares $26.15 thousand +3,493.5%N/A0.2 $0.09 7/31/20207,700 shares $553.63 -67.4%N/A0 $0.07 PVCT Short Interest - Frequently Asked Questions What is Provectus Biopharmaceuticals' current short interest? Short interest is the volume of Provectus Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 500 shares of PVCT short. 0.00% of Provectus Biopharmaceuticals' shares are currently sold short. Learn More on Provectus Biopharmaceuticals' current short interest. What is a good short interest percentage for Provectus Biopharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Provectus Biopharmaceuticals' floating shares are currently sold short. Is Provectus Biopharmaceuticals' short interest increasing or decreasing? Provectus Biopharmaceuticals saw a decrease in short interest in June. As of June 30th, there was short interest totaling 500 shares, a decrease of 97.1% from the previous total of 17,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Provectus Biopharmaceuticals' short interest compare to its competitors? 0.00% of Provectus Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Provectus Biopharmaceuticals: Korro Bio, Inc. (18.40%), FitLife Brands Inc. (1.23%), Nkarta, Inc. (11.60%), ALT5 Sigma Corporation (5.67%), Fate Therapeutics, Inc. (8.81%), Kyverna Therapeutics, Inc. (10.43%), Protalix BioTherapeutics, Inc. (4.74%), C4 Therapeutics, Inc. (7.65%), Milestone Pharmaceuticals Inc. (4.58%), Oncolytics Biotech Inc. (2.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Provectus Biopharmaceuticals stock? Short selling PVCT is an investing strategy that aims to generate trading profit from Provectus Biopharmaceuticals as its price is falling. PVCT shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Provectus Biopharmaceuticals? A short squeeze for Provectus Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PVCT, which in turn drives the price of the stock up even further. How often is Provectus Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PVCT, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies KRRO Short Interest Data FTLF Short Interest Data NKTX Short Interest Data ALTS Short Interest Data FATE Short Interest Data KYTX Short Interest Data PLX Short Interest Data CCCC Short Interest Data MIST Short Interest Data ONCY Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:PVCT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
